| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 130.04 | 0.00 (0.00%) | 67.67 - 133.00 | 10.6 thousand (Below Avg) |
Market data as of 4:00PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 130.04 |
| Day's Range | -- - -- |
| Market Cap | 16.6B |
| Avg Volume (10 Day) | 3.6M |
| Price/Earnings (Trailing 12 Mo.) | 66.5x |
| Earnings Per Share (Trailing 12 Mo.) | 1.29 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company
PR Newswire - Monday 05/20/2013 7:06 AM ET
Announcement Under Irish Takeover Rules Relevant Securities in Issue
PR Newswire - Tuesday 05/14/2013 1:55 AM ET
Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA
PR Newswire - Monday 05/13/2013 9:00 AM ET
Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Monday 05/13/2013 8:00 AM ET
Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
PR Newswire - Friday 05/10/2013 2:45 PM ET
Actavis Confirms District Court Ruling In Generic Lialda® Patent Suit
PR Newswire - Thursday 05/09/2013 4:15 PM ET
Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
PR Newswire - Tuesday 05/07/2013 8:52 AM ET
Actavis to Host Annual Meeting of Stockholders on May 10, 2013
PR Newswire - Friday 05/03/2013 8:00 AM ET
| ACT | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 20.14% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 1.78 | |
| LT Debt/Equity | 1.73 | |
| Earnings Yield | 1.50% | |
| Price/Sales | 2.64 |
| Company | Last | Change |
|---|---|---|
| Mylan Inc | 31.55 | 0.00% |
| Salix Pharmaceuticals Ltd | 59.47 | 0.00% |
| Akorn Inc | 14.55 | 0.00% |
| Momenta Pharmaceuticals Inc | 13.26 | 0.00% |
| Ligand Pharmaceuticals Inc | 27.38 | 0.00% |
Data is delayed by at least 15 min.